Lv3
218 积分 2024-02-18 加入
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and Adolescents
1个月前
已完结
EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer
2个月前
已完结
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
8个月前
已完结
MA04.02 Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC
9个月前
已关闭
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
9个月前
已完结
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
11个月前
已完结
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
1年前
已完结
皖公网安备34019202002308
